Brazil Threatens to Break Patents, Produce Antiretroviral Drugs If Companies Do Not Reduce Prices
August 29, 2003
Brazil has threatened to break the patents on three antiretroviral drugs and begin producing generic versions of the medicines if drug makers Abbott Laboratories, Roche and Merck do not cut their prices by 50%, according to the AP/Las Vegas Sun. Brazilian Health Minister Humberto Costa issued an "ultimatum" to the companies, saying that if the companies do not offer an "acceptable" plan by tomorrow, Brazil will explore making generic versions of the drugs or consider importing them, according to the AP/Sun. The drugs in question -- lopinavir, made by Abbot; nelfinavir, produced by Roche; and efavirenz, made by Merck -- represent 63% of Brazil's $172 million annual budget for antiretroviral drugs, according to the AP/Sun. The companies responded to Costa's threat by saying that they already offer Brazil reduced prices on the drugs. Abbott offered to reduce the price of lopinavir by 1.3% to $1.48 per dose. Roche sells nelfinavir to Brazil for 53 cents per dose, and Merck supplies efavirenz for $2.10 per dose. However, Marcia Lage, a spokesperson for the Brazil's National STD/AIDS Programme of the Ministry of Health, said that the government can produce individual doses of the drugs for 25 cents, 27 cents and 87 cents per dose, respectively. Abbott in a statement said that it is "hopeful of a positive end to the current negotiations." Merck spokesperson Anita Larsen said that the company is waiting for a "specific price cut proposal" from Brazil, according to the AP/Sun. Both Abbott and Merck say that they offer Brazil the lowest price on their antiretroviral drugs outside of the prices offered to African nations and other countries designated as least developed by the United Nations. Roche said that it also offers the drugs to Brazil at reduced prices.
Brazil to Distribute More Than Three Million Condoms to High School Students for HIV, Pregnancy Prevention
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.